Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment

• Autor(a) principal: de Matos, Djamile Cordeiro [UNESP]
• Data de Publicação: 2012
• Outros Autores: Abreu de Ribeiro, Livia Carolina [UNESP], Tansini, Aline [UNESP], Ferreira, Lucas Souza [UNESP], Polesi Placeres, Marisa Campos [UNESP], Luis Colombo, Lucas, Carlos, Iracilda Zeppone [UNESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1186/1472-6882-12-107; http://hdl.handle.net/11449/7269
• topic: Pulchellin; Breast cancer; Cytokines; Immune system

Background: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer.Methods: The percentage of dendritic cells and CD4(+) and CD8(+) T cells in the spleen (flow cytometry), cytokines' release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 mu g/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey's post hoc test.Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-gamma and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-beta levels were decreased. There was also an increase in macrophage's activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively).Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.